BioNTech Buys CureVac in $1.25 Billion mRNA Cancer Bet
BioNTech has agreed to acquire German biotech rival CureVac in a $1.25 billion all-stock deal, strengthening its ambitions in mRNA-based ...
Read moreDetails
BioNTech has agreed to acquire German biotech rival CureVac in a $1.25 billion all-stock deal, strengthening its ambitions in mRNA-based ...
Read moreDetails
